drug
BALVERSA
updated 3mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying BALVERSA
- phase2An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
- phase1A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
- phase3A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
- phase2Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- phase2A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
- phase2A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
- phase2A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- phase2Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that